Teresa Amaral, Medical Oncologist at the University Hospital Tübingen, shared on LinkedIn:
“Next week, 17.11.2026 at 12.30, I will be participating in:
Panel 1: The EU Biotech Act – Europe’s opportunity to reclaim innovation leadership representing ESMO – European Society for Medical Oncology.
Questions that will be addressed:
- Can the Biotech Act provide the regulatory certainty and investment signals needed to strengthen Europe’s life sciences competitiveness?
- How can the EU improve the speed and attractiveness of clinical trials while maintaining trust and high regulatory standards?
- What would success look like for the Biotech Act five years after its implementation?
See the full agenda here.
PANEL 1:
- Thomas Van Cangh – Deputy Head of Unit, Policy Strategy, DG SANT, European Commission
- Antonella Cardone – CEO, Cancer Patients Europe
- Dr Teresa Amaral – Head of the Early Phase Clinical Trials and the Skin Cancer and Sarcoma Program at Institut de Cancérologie Public Strauss Europe, Strasbourg, and member of the European Society for Medical Oncology
- Pr Elizabeth Macintyre
- Mike Morrissey – Associate Vice President, Global Public Policy Europe and Canada MSD, and Chair, EuropaBio
- Sascha Berger – Founder and Managing Partner, BergerInvest
You may also be interested in:
Teresa Amaral Discusses the Value and Shortcomings of the ESMO-MCBS at the ESMO/SBOC Joint Session